Search Results
Your search for The,The matches 34082 pages
Showing 551 - 600Effect of False-Positives on Adherence to Subsequent Breast Cancer Screening
Patients may be less likely to return for subsequent screening mammography following a false-positive recall for additional imaging or biopsy, according to a recent study published by Miglioretti et al in the Annals of Internal Medicine. The findings raised concerns regarding the potential...
Chronic Conditions Could Delay Lung Cancer Diagnoses
Investigators have revealed that patients with certain chronic conditions may face delays in being diagnosed with lung cancer, according to a recent study published by Rogers et al in the British Journal of Cancer. Background Lung cancer is currently one of the leading causes of cancer-related...
Menopausal Hormone Therapy and Risk of Ovarian and Endometrial Cancers
In a long-term follow-up of Women’s Health Initiative (WHI) randomized trials reported in the Journal of Clinical Oncology, Rowan T. Chlebowski, MD, PhD, and colleagues identified risks of ovarian and endometrial cancers associated with the use of menopausal hormone therapy. Study Details The...
T-DXd Effective for Breast Tumors With HER2-Low and HER2-Ultralow Expression in Earlier Line of Therapy
In patients with hormone receptor–positive metastatic breast cancers with HER2-low or HER2-ultralow expression, treatment with the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was found to be superior to chemotherapy after one or more lines of endocrine therapy. In...
Adjuvant Pembrolizumab vs Placebo in Stage III Melanoma: Long-Term Health-Related Quality of Life
In an analysis from the phase III EORTC 1325-MG/KEYNOTE-054 trial reported in The Lancet Oncology, Bührer et al found that adjuvant pembrolizumab was not associated with significant differences in long-term health-related quality of life (HRQOL) compared with placebo in patients with stage III...
Oral Cannabis Extract for Refractory Chemotherapy-Induced Nausea and Vomiting
In an Australian phase II/III trial reported in the Journal of Clinical Oncology, Grimison et al found that oral cannabis extract improved the antiemetic complete response rate vs placebo in patients with cancer who had refractory chemotherapy-induced nausea and vomiting (CINV) despite use of...
Early-Onset Colorectal Cancer: Rurality and Poverty May Be Linked to Lower Survival
Patients with early-onset colorectal cancer living in rural vs urban areas were found to have a lower likelihood of 5-year survival, with persistent poverty compounding this association in some age groups, according to an analysis published in a research letter by Tsai et al in JAMA Network Open....
Structural Racism and Cancer Risk From Traffic-Related Air Pollution
Multiple aspects of structural racism may contribute to an increased exposure to carcinogenic traffic-related air pollution, according to a recent study published by White and Ekenga in Cancer. Background High levels of traffic-related air pollutants have been linked to an elevated risk of...
What Is the Better Target for Bispecific Antibodies in Multiple Myeloma: BCMA or GPRC5D?
For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor class C group 5 member D (GPRC5D). Which is the preferred target? This question was addressed at the 2024...
Impact of Breast Cancer Screening Interval on Stage at Diagnosis and Overall Survival
Annual mammographic screening appeared to be associated with a reduced risk of late-stage breast cancer and an overall survival benefit across clinical and demographic subgroups of patients older than age 40, according to an observational analysis reported by Zuley et al in the Journal of Clinical...
Genomic Determinants of Relapse in Childhood ALL
In a study reported in the Journal of Clinical Oncology, Chang et al identified potential genomic determinants of relapse risk in pediatric acute lymphoblastic leukemia (ALL). As stated by the investigators, “Although cure rates for childhood ALL exceed 90%, ALL remains a leading cause of cancer...
Ruxolitinib for Corticosteroid-Refractory Sclerotic Chronic GVHD
In a phase II study reported in the Journal of Clinical Oncology, Vijaya Raj Bhatt, MS, MBBS, and colleagues found that ruxolitinib produced responses in patients with corticosteroid-refractory sclerotic chronic graft-vs-host disease (GVHD) after transplantation for hematologic malignancies. Study ...
HPV Vaccination Rate Among Young Female Patients With Psychiatric Diagnoses
The rate of human papillomavirus (HPV) vaccination may be lower among female individuals with mental health issues or neurodevelopmental conditions compared with their peers, according to a recent study published by Hu et al in The Lancet Public Health. Background The HPV vaccine is capable of...
Preclinical Study Examines Novel Pancreatic Cancer Treatment
Early-stage research demonstrated the synergistic effects of a novel nanoparticle drug–delivery system to activate an immune pathway in combination with tumor-targeting agents in mice with pancreatic ductal adenocarcinoma, according to a preclinical study published by Chibaya et al in Science...
FDA Approves Cancer Biomarker Test, Companion Diagnostic Indications
The U.S. Food and Drug Administration (FDA) has approved the in vitro diagnostic TruSight Oncology (TSO) Comprehensive test and its first two companion diagnostic indications. This targeted sequencing panel interrogates over 500 genes to profile a patient's solid tumor, helping to increase the...
ICI-Based Strategies in Advanced, Progressing EGFR-Mutated NSCLC
As reported in The Lancet Oncology by Zhao et al, meta-analyses of trials of immune checkpoint inhibitors (ICIs) in patients with advanced EGFR-mutated non–small cell lung cancer (NSCLC) progressing on EGFR tyrosine kinase inhibitor (TKI) treatment indicate that the optimal treatment strategy is...
Previously Untreated Cancer of Unknown Primary: Site-Specific Therapy Guided by a 90-Gene Expression Assay
In a Chinese single-center trial (Fudan CUP-001) reported in The Lancet Oncology, Liu et al found that site-specific therapy guided by a 90-gene expression assay improved progression-free survival vs empirical chemotherapy in previously untreated patients with cancer of unknown primary (CUP) who...
Can a Blood Test Predict Obesity-Related Cancer Risk in Patients With Type 2 Diabetes?
Researchers have found that a blood test may effectively identify patients with type 2 diabetes who may be at a higher risk of developing certain cancers, according to new findings to be presented by Bennetsen et al at the upcoming European Association for the Study of Diabetes Annual Meeting 2024...
Many Women Unaware of Preventive Benefits of Diet for Breast Cancer Risk
Just 28% of U.S. women may be aware that a healthful diet can lower the risk of developing breast cancer, according to a recent survey conducted by the Physicians Committee for Responsible Medicine and Morning Consult. Background The Physicians Committee for Responsible Medicine is a national...
Adjuvant Everolimus in Localized Papillary and Chromophobe Non–Clear Cell Renal Cell Carcinoma
In a subgroup analysis of the EVEREST trial reported in JAMA Network Open, Gulati et al found that adjuvant everolimus did not improve recurrence-free survival vs placebo in patients with localized papillary or chromophobe non–clear cell renal cell carcinoma (RCC). Study Details In the trial,...
Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer
In an Austrian study reported in the Journal of Clinical Oncology, Brunner et al identified the incidence of medication-related osteonecrosis of the jaw over 20 years of follow-up in patients with breast cancer who had bone metastases and were receiving antiresorptive medication. Study Details and...
Remembering a Pioneer in Melanoma and Immunotherapy: Jeffrey S. Weber, MD, PhD, FASCO
Jeffrey S. Weber, MD, PhD, FASCO, an internationally recognized pioneer in melanoma and cancer immunotherapy, died on August 19, 2024, according to an announcement from the Melanoma Research Foundation. He most recently served as Deputy Director of the Laura and Isaac Perlmutter Cancer Center at...
Cancer Has Robbed Me of My Fertility and My Olympic Dreams
I was a track and field athlete throughout college, and my goal was to try out for the Olympics, but cancer had other plans for me. In 2010, while in my senior year in college, I began having sharp, shooting pains in my shoulders, which I initially attributed to overzealous training. But the pain...
Olaparib May Be Effective Without Hormone Therapy in Some Men With Biochemically Recurrent Prostate Cancer
Olaparib may be effective in treating men with biochemically recurrent prostate cancer without accompanying hormone therapy, according to a novel study published by Marshall et al in JAMA Oncology. Background Although most men with localized prostate cancer can be cured with surgery or primary...
Pregnancy-Associated Cancer Incidence and Risks of Adverse Obstetric, Perinatal Outcomes
Women with breast cancer during pregnancy may have a good prognosis and a low risk of adverse obstetric and perinatal outcomes, according to three recent studies published by Lundberg et al in Acta Obstetricia et Gynecologica Scandinavica, Gkekos et al in ESMO Open, and Lundberg et al in Acta...
Ponatinib With Chemotherapy for Newly Diagnosed Philadelphia Chromosome–Positive ALL
On March 19, 2024, ponatinib (Iclusig) was granted accelerated approval for use with chemotherapy in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL).1 Ponatinib is a multitargeted kinase inhibitor. Supporting Efficacy Data and How It Is Used Approval ...
Inotuzumab Ozogamicin for Pediatric Acute Lymphoblastic Leukemia
On March 6, 2024, the anti-CD22 monoclonal antibody inotuzumab ozogamicin (Besponsa), which is bound to a toxic natural calicheamicin, was approved for pediatric patients aged 1 year or older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.1 Supporting...
CAR T-Cell Therapy in Refractory Follicular Lymphoma
On May 15, 2024, lisocabtagene maraleucel (Breyanzi) was granted accelerated approval for adults with relapsed or refractory follicular lymphoma with two or more prior lines of systemic therapy.1 The agent is a CD19-directed genetically modified autologous T-cell immunotherapy. Supporting Efficacy...
Hypofractionated vs Conventionally Fractionated Radiation After Implant-Based Breast Reconstruction
In a trial reported in JAMA Oncology, Julia S. Wong, MD, and colleagues found that hypofractionated postmastectomy radiation therapy did not improve outcomes in the physical well-being domain of the Functional Assessment of Cancer Therapy–Breast (FACT-B) assessment vs conventionally fractionated...
Disparities in Exposure to Tobacco Content on Streaming Platforms
The risk of encountering tobacco products being advertised, marketed, or promoted on streaming services based on race, ethnicity, socioeconomic status, and smoking habits was identified in a recent study published by Onyeaka et al in JAMA Network Open. Background The World Health Organization...
Early Interventions May Improve Long-Term Academic Achievement in Pediatric Brain Tumor Survivors
Investigators have found that providing early developmental resources may help reduce the adverse effects of brain tumors and cancer therapy on the academic achievement of young pediatric cancer survivors, according to a recent study published by Somekh et al in the Journal of the National Cancer...
The Evolving Epidemiology of Gastrointestinal Stromal Tumors in Major Organ Sites
Based on a descriptive, U.S. population–based cohort study reported in JAMA Network Open by Alvarez et al, over the past 2 decades, the incidence of gastrointestinal stromal tumors in major organ sites has increased among several patient populations. The findings may assist in directing future...
Inoperable Stage III NSCLC: Adaptive Radiotherapy Based on FDG-PET Tumor Residual Uptake
In a French phase II study (RTEP7–IFCT-1402) reported in The Lancet Oncology, Vera et al found that adaptive radiotherapy based on fluorine F-18–labeled fluorodeoxyglucose (FDG)–positron-emission tomography (PET) residual uptake appeared to improve local disease control compared with standard...
BTK Degraders and CELMoDs: Novel Mechanisms Overcoming Resistance in Hematologic Malignancies
Despite advances in targeted therapies for hematologic malignancies, drug resistance and persistent side effects continue to challenge clinicians and limit patient outcomes, underscoring the urgent need for novel therapeutic approaches. At the 2024 Pan Pacific Lymphoma Conference, Marc S. Hoffmann, ...
Novel Insights Into Multiple Myeloma Progression
Researchers have offered a comprehensive understanding of the progression of multiple myeloma from a treatable condition to a high-risk disease by providing insights into its genetic diversity and subtypes, according to a recent study published by Skerget et al in Nature Genetics. Background...
Targetable Variant Found in Chinese Patients With Ovarian Cancer
Researchers may have uncovered the germline mutational landscape of Chinese patients with ovarian cancer and identified an enriched RAD51D variant in these patients, according to a recent study published by Feng et al in JCO Global Oncology. The findings could serve as a critical reference for...
Role of Patient-Reported Outcome Measures in Assessing Chemotherapy-Induced Peripheral Neuropathy
A cohort study reported in JAMA Network Open by Li et al demonstrated the superiority of patient-reported outcome measures vs other methods in assessing nerve damage in patients with cancer who underwent neurotoxic chemotherapy. “Accordingly, the adoption of chemotherapy-induced peripheral...
Menin Inhibitor in KMT2A-Rearranged Relapsed or Refractory Acute Leukemia
In a phase I/II study (AUGMENT-101) reported in the Journal of Clinical Oncology, Issa et al found that revumenib, an oral small-molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, was active in patients with KMT2A-rearranged (KMT2A) relapsed or refractory acute...
Advanced Biliary Tract Cancers: Bevacizumab/Erlotinib Maintenance vs Active Surveillance
In an Indian phase II trial (BEER BTC) reported in the Journal of Clinical Oncology, Ramaswamy et al found that maintenance therapy with bevacizumab/erlotinib improved progression-free survival vs active surveillance in patients with advanced biliary tract cancers who had at least stable disease...
First-Line Nivolumab/Relatlimab vs Nivolumab/Ipilimumab in Advanced Melanoma
In an analysis reported in the Journal of Clinical Oncology, Georgina V. Long, PhD, MBBS, and colleagues performed an indirect comparison of outcomes with first-line nivolumab/relatlimab vs nivolumab/ipilimumab for advanced melanoma using patient-level data from trials supporting approval of the...
Can Mindful Breathing Reduce the Intensity of Cancer-Related Pain?
Twenty minutes of mindful breathing, which focuses a person’s attention on their breath, seems to rapidly reduce the intensity and unpleasantness of cancer pain and relieve the associated anxiety, suggest findings from a small comparative study published by Tan et al in BMJ Supportive &...
AI May Help Uncover Relationship Between Radiation Therapy for NSCLC and Cardiac Arrhythmia
Artificial intelligence (AI) tools may be used to better understand the risk of specific cardiac arrhythmias when various parts of the heart are exposed to different thresholds of radiation as part of a treatment plan for non–small cell lung cancer (NSCLC), according to a recent study published by...
Exploring Targeted Therapies in Multiple Myeloma
Investigators have explored the multifaceted nature of multiple myeloma and the potential of targeted therapies to treat patients with the disease, as summarized in a review published by Lu et al in Molecular Biomedicine. Background Multiple myeloma is a complex hematologic malignancy with...
Metastatic Pancreatic Adenocarcinoma: Addition of Devimistat to mFFX
As reported in the Journal of Clinical Oncology, Philip et al found that the phase III AVENGER 500 study showed no overall survival benefit with devimistat plus modified fluorouracil, oxaliplatin, irinotecan, and leucovorin (mFFX) vs FFX in patients with metastatic pancreatic adenocarcinoma. As...
Breast-Conserving Surgery With or Without Postoperative Radiotherapy in Early-Stage Breast Cancer: 30-Year Update
As reported in The Lancet Oncology by Williams et al, long-term follow-up of the phase III Scottish Breast Conservation Trial indicated that postoperative radiotherapy was associated with a significantly reduced risk of ipsilateral recurrence vs no radiotherapy in patients undergoing...
FDA Approves Lazertinib With Amivantamab-vmjw for EGFR-Mutated NSCLC
The U.S. Food and Drug Administration (FDA) has approved the EGFR inhibitor lazertinib (Lazcluze) in combination with the EGFR/MET-targeting bispecific antibody amivantamab-vmjw (Rybrevant) for the first-line treatment of patients with locally advanced or metastatic non–small cell lung cancer...
Acalabrutinib Plus Chemoimmunotherapy Improves Progression-Free Survival in Older Patients With Mantle Cell Lymphoma
Combining Bruton’s tyrosine kinase (BTK) inhibition with chemoimmunotherapy induction significantly extended progression-free survival for older patients with mantle cell lymphoma, and there was also a trend toward improvement on the overall survival benefit, according to data presented during the...
SCOTUS Ruling Upends Country’s Regulatory Framework, Threatens to Complicate and Delay Health-Care Delivery
The Association for Clinical Oncology (ASCO) has serious concerns about the impact of the Supreme Court’s rulings in Loper Bright Enterprises v Raimondo and Relentless, Inc. v Department of Commerce on cancer care. These decisions overturned the “Chevron deference” or “Chevron doctrine,” a legal...
ASCO Guideline Update Highlights the Importance of Early Integration of Palliative Care for Patients With Cancer
Growing awareness of the benefits of palliative care in patients with cancer has prompted ASCO to update its recommendations for clinicians, patients, caregivers, and health-care organizations on integrating palliative care in oncology.1 The updated guideline reinforces prior recommendations in the ...
Can Alternative Criteria Help Identify Patients Who May Benefit From Lung Cancer Screening?
Researchers have developed an alternative set of simple criteria using a prediction model to identify groups of patients who may benefit most from lung cancer screening but are disproportionately excluded by current eligibility criteria, according to a new study published by Kearney et al in the...
